Literature DB >> 3279499

Adverse effects of the fluoroquinolones.

H Halkin1.   

Abstract

Data on adverse reactions due to the quinolone antibacterial agents--ciprofloxacin, ofloxacin, pefloxacin, norfloxacin, and enoxacin--observed in a patient sample of approximately 30,000 are reviewed. Overall rates of adverse reactions were 4.0%-8.0%, and adverse reactions necessitated discontinuation of therapy in 1.0%-2.6% of patients. Patterns of organ-system involvement and of signs and symptoms were quite similar, with gastrointestinal effects predominating (nausea, vomiting, diarrhea, or abdominal pain in 1.0%-5.0% of the patients), followed by effects on the central nervous system (dizziness, headache, and/or insomnia in 0.1%-0.3% of the patients) and skin (0.5%-2.2% of the patients). Elevation in levels of hepatic enzymes occurred in 1.8%-2.5% of the patients, azotemia in 0.2%-1.3%, and eosinophilia in 0.2%-2.0%. These adverse effects were reversible after drug withdrawal and were generally not dose-dependent. Within the constraints of the relatively small number of well-documented patients and the unique mechanism of action of these antimicrobial agents, the safety profile of these drugs seems to make them acceptable for use when their administration is well directed and specific. In addition, close surveillance for new phenomena should be maintained.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3279499     DOI: 10.1093/clinids/10.supplement_1.s258

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  24 in total

Review 1.  Drug-induced rheumatic disorders: incidence, prevention and management.

Authors:  P Vergne; P Bertin; C Bonnet; C Scotto; R Trèves
Journal:  Drug Saf       Date:  2000-10       Impact factor: 5.606

2.  Structure-epileptogenicity relationship of quinolones with special reference to their interaction with gamma-aminobutyric acid receptor sites.

Authors:  K Akahane; M Sekiguchi; T Une; Y Osada
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

Review 3.  Quinolone antimicrobial agents: adverse effects and bacterial resistance.

Authors:  J S Wolfson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-12       Impact factor: 3.267

4.  Open, randomized comparison of pefloxacin and cefotaxime in the treatment of complicated urinary tract infections.

Authors:  C Timmerman; I Hoepelman; J de Hond; T Boon; L Schreinemachers; H Mensink; J Verhoef
Journal:  Infection       Date:  1992 Jan-Feb       Impact factor: 3.553

5.  Protective effects of local administration of ciprofloxacin on the risk of pneumococcal meningitis after cochlear implantation.

Authors:  Benjamin P C Wei; Roy M Robins-Browne; Robert K Shepherd; Kristy Azzopardi; Graeme M Clark; Stephen J O'Leary
Journal:  Laryngoscope       Date:  2006-12       Impact factor: 3.325

6.  Lobular panniculitis associated with ciprofloxacin.

Authors:  E Rodríguez; J A Martínez; M Torres; A Nubiola; J Buges
Journal:  BMJ       Date:  1990-06-02

7.  Dose-ranging study of fleroxacin for treatment of uncomplicated Chlamydia trachomatis genital infections.

Authors:  W R Bowie; V Willetts; D W Megran
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

8.  Adverse reactions in a dose-ranging study with a new long-acting fluoroquinolone, fleroxacin.

Authors:  W R Bowie; V Willetts; P J Jewesson
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

9.  Clinical trial of ofloxacin alone and in combination with dapsone plus clofazimine for treatment of lepromatous leprosy.

Authors:  B Ji; E G Perani; C Petinom; L N'Deli; J H Grosset
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

Review 10.  Clinical pharmacokinetics of ciprofloxacin.

Authors:  K Vance-Bryan; D R Guay; J C Rotschafer
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.